105806-11-9

Basic information

• Product Name: 5-Bromo-6-chloro-2-methylpyrimidin-4-ol
• Synonyms: 5-Bromo-6-chloro-2-methylpyrimidin-4-ol;5-Bromo-6-chloro-4-hydroxy-2-methylpyrimidine;5-bromo-6-chloro-2-methylpyrimidin-4(1H)-one;5-bromo-6-chloro-2-methylpyrimidin-4-ol（WS204678）
• CAS NO: 105806-11-9
• Molecular Formula: C₅H₄BrClN₂O
• Molecular Weight: 223.45506
• Mol File: 105806-11-9.mol

Chemical Properties

• Melting Point: 246～248℃
• Appearance: /
• CAS DataBase Reference: 5-Bromo-6-chloro-2-methylpyrimidin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-6-chloro-2-methylpyrimidin-4-ol(105806-11-9)
• EPA Substance Registry System: 5-Bromo-6-chloro-2-methylpyrimidin-4-ol(105806-11-9)

Safety Data

• Hazardous Substances Data: 105806-11-9(Hazardous Substances Data)

Upstream product

• 17551-52-9 2-methyl-4-hydroxy-6-chloropyrimidine 

Relevant articles and documents

Chemistry and Positive Inotropic Effect of Pelrinone and Related Derivatives. A Novel Class of 2-Methylpyrimidones as Inotropic Agents

A novel series of pyrimidine derivatives was synthesized and evaluated for positive inotropic activity.Inotropic and chronotropic effects were determined in vitro in cat papillary muscle and right atrium, respectively.Selected compounds were then evaluated in vivo in a dog heart failure model.Changes in ventricular dP/dt, heart rate, and blood pressure were monitored.Several of these agents produced relatively minor changes in heart rate.This class of agents demonstrated a varying degree of vasodilator effects concomitant with increases in ventricular contractility.The most potent analogues, 9, 48, and 49, were evaluated orally in conscious dogs with implanted Konisberg pressure transducers, and their effect on left ventricular dP/dt was compared with that of milrinone.Mechanistically, the agents of this novel class appear not to mediate their effect either via β-receptors or inhibition of Na(+)/K(+)-ATPase.A major component of their inotropic effect is mediated by the inhibition of cardiac phosphodiesterase (PDE)-Fr.III.This was clearly demonstrated by 9, 48, and 49.Compound 48 was found to be the most potent inhibitor of PDE-Fr.III from among the compounds tested in this assay.

5-substituted-6-aminopyrimidines, composition and uses as cardiotonic agents for increasing cardiac contractility

Herein is disclosed amino-pyrimidine derivatives, therapeutically acceptable acid addition salts thereof, processes for their preparation, methods of using the derivatives and pharmaceutical compositions. The derivatives are useful for increasing cardiac contractility in a mammal.